Respinova

Company Overview

Snapshot

Founded in September 2008 by Yuval Avni, Respinova operates with 1–10 employees. The company has secured $7.76 million in total capital across four funding rounds. A significant milestone for Respinova was receiving FDA 510(k) clearance for its PulseHaler device in April 2021.

Business overview

Respinova develops noninvasive technology for treating chronic obstructive pulmonary disorder (COPD) and enhancing inhaled therapeutics. Its core product, the PulseHaler, utilizes proprietary multi-frequency air pressure pulse technology designed to improve lung function, exercise capacity, and quality of life for COPD patients, as well as to deliver drugs more effectively to the lung periphery. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving patients and providers in the healthcare industry.

Strategic signal

In April 2021, Respinova received FDA 510(k) clearance for its PulseHaler device. This regulatory approval is a critical validation of the technology's safety and efficacy, signaling to investors and the market that the device is ready for commercialization and has the potential to become a standard of care in COPD management.

Company Intelligence Q&A

What is Respinova's primary product?

Respinova's primary product is the PulseHaler, a noninvasive device designed to treat chronic obstructive pulmonary disorder (COPD) and improve the delivery of inhaled therapeutics.

When did Respinova receive FDA clearance for its PulseHaler?

Respinova was granted FDA 510(k) clearance for its PulseHaler device in April 2021.

Has Respinova's technology been clinically validated?

Yes, Respinova's technology has been successfully validated in two clinical studies, demonstrating its ability to improve lung function, exercise capacity, and quality of life for COPD patients, and to deliver drugs more effectively.

What was the role of the European Union's Horizon 2020 program in Respinova's development?

The commercialization of Respinova's PulseHaler was co-funded by the European Union's Horizon 2020 program, which also provided a grant in February 2019.

What is the current status of Respinova?

Respinova ceased to operate in March 2025.